Chest ACCP Career Connection
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     

Guest Access | Sign In via User Name/Password
This Article
Right arrow Full Text Free
Right arrow Full Text (PDF) Free
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Article Archive
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (14)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Meyer, K. C.
Right arrow Articles by Love, R. B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Meyer, K. C.
Right arrow Articles by Love, R. B.
(Chest. 2001;119:137-143.)
© 2001 American College of Chest Physicians

Vascular Endothelial Growth Factor in Human Lung Transplantation*

Keith C. Meyer, MD, FCCP; Andrew L. Cardoni, BS; Zhuzai Xiang, MD; Richard D. Cornwell, MD and Robert B. Love, MD, FCCP

* From the Departments of Medicine (Drs. Meyer, Xiang, and Cornwell, and Mr. Cardoni) and Surgery (Dr. Love), University of Wisconsin Medical School, Madison, WI.

Correspondence to: Keith C. Meyer, MD, FCCP, Department of Medicine, H6/380 Clinical Sciences Center, 600 Highland Ave, Madison, WI 53792; e-mail: kcm{at}medicine.wisc.edu

Study objectives: To determine levels of the vascular endothelial growth factor (VEGF) isoform consisting of 165 amino acids (VEGF165) in BAL fluid (BALF) from lung transplant recipients (LTXs).

Design: Bronchoscopy with BAL was performed on LTXs and normal volunteers (NVs).

Setting: University hospital.

Participants: LTXs (n = 57) and NVs (n = 15).

Measurements and result: VEGF165 concentrations in BALF were higher (mean ± SEM, 240 ± 32 pg/mL) for NVs (n = 15) vs 133 ± 14 pg/mL for LTXs (n = 37) who were stable without evidence of significant rejection or infection at 6 months after transplantation (p < 0.0001). BALF VEGF concentrations sampled at 24 to 48 h, 2 weeks, 4 weeks, and 6 months after transplantation for 11 LTXs who lacked rejection or infection at any time point were 71 ± 8 pg/mL, 80 ± 20 pg/mL, 82 ± 13 pg/mL, and 167 ± 31 pg/mL, respectively. VEGF concentrations in BALF for LTXs with cytomegalovirus (CMV) pneumonia were 55 ± 12 pg/mL (n = 10), 117 ± 33 pg/mL for grade A3 acute rejection (n = 9), and 82 ± 17 pg/mL (n = 14) for active bronchiolitis obliterans syndrome (BOS). Concentrations of VEGF in BALF at 6 months for the 32 stable recipients with bilateral lung transplantation were significantly higher for those with higher values for FEV1, and BALF VEGF concentrations were significantly lower in BALF at 6 months for those recipients who subsequently went on to develop BOS (86 ± 19 pg/mL) vs those who did not (158 ± 18 pg/mL; p = 0.03). Serum concentrations of VEGF did not correlate with VEGF concentrations in BALF, but serum VEGF was 291 ± 62 pg/mL at 10 to 14 days after transplantation vs 130 ± 20 pg/mL at 4 weeks for nine LTXs with paired samples (p < 0.02). Serum VEGF concentrations for NVs (n = 15) were 102 ± 15 pg/mL vs 94 ± 17 for stable LTXs (n = 12) at 24 weeks after transplantation and 123 ± 33 pg/mL for LTXs with active BOS (n = 10).

Conclusions: BALF VEGF concentrations are particularly depressed at early time points following lung transplantation, gradually improve in the absence of significant rejection or infection, and are lower with active rejection or CMV pneumonia.

Key Words: BAL • lung transplantation • vascular endothelial growth factor




This article has been cited by other articles:


Home page
Am. J. Respir. Crit. Care Med.Home page
R. Krebs, J. M. Tikkanen, A. I. Nykanen, J. Wood, M. Jeltsch, S. Yla-Herttuala, P. K. Koskinen, and K. B. Lemstrom
Dual Role of Vascular Endothelial Growth Factor in Experimental Obliterative Bronchiolitis
Am. J. Respir. Crit. Care Med., June 15, 2005; 171(12): 1421 - 1429.
[Abstract] [Full Text] [PDF]


Home page
ThoraxHome page
G D Perkins, J Roberts, D F McAuley, L Armstrong, A Millar, F Gao, and D R Thickett
Regulation of vascular endothelial growth factor bioactivity in patients with acute lung injury
Thorax, February 1, 2005; 60(2): 153 - 158.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2001 by the American College of Chest Physicians.